A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
Crossref DOI link: https://doi.org/10.1007/s40273-016-0447-3
Published Online: 2016-09-03
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wade, Ros http://orcid.org/0000-0002-8666-8110
Hodgson, Robert
Biswas, Mousumi
Harden, Melissa
Woolacott, Nerys
Funding for this research was provided by:
Health Technology Assessment Programme (14/206/01)
License valid from 2016-09-03